http://www.ecancermedicalscience.com/This RSS feed lets you know when new articles are added to the ecancermedicalscience website.dev@2cs.com;kelly@brandcastmedia.com;linda.cairns@ifom-ieo-campus.it;gordon.mcvie@ieo.it;jonathan@ecancermedicalscience.com;enhttp://www.ecancermedicalscience.com/view-article.asp?doi=10.3332/ecancer.2010.177Tue, 26 Jan 2010 00:00:00 GMT]]>http://www.ecancermedicalscience.com/view-article.asp?doi=10.3332/ecancer.2010.164Wed, 3 Feb 2010 00:00:00 GMT
The latest innovation in cancer treatments are targeted biological treatments, joining the current arsenal of surgery, radiotherapy and chemotherapy, particularly significant
in latter stage cancers associated with very poor survival.

Despite this latest breakthrough in cancer treatment, this has in fact only opened the door to beginning to understand the complexity of cancer on a molecular and genetic basis. Oncology research and development (R&D) has the highest failure rate for new molecular entities (NME) and significantly higher development costs. Although tremendous scientific and economic barriers exist, the oncology development market
has increased two-fold over the past five years.

This report aims to map current oncology R&D funding and management, primarily in Europe and the USA, to examine public-private relationships, current oncology R&D strategies and oncology innovation policies. Its objectives are:

- To map current funding and management of oncology R&D via questionnaire
surveys and interviews of oncology experts;
- To produce a high-resolution bibliometric analysis of oncology drug R&D in
order to better understand the public-private mix in research activity;
- To investigate the cumulative life-time funding of specific oncology drugs;
- To review current public policy affecting oncology drug R&D, specifically, public
R&D investment policies, transnational investment policies, regulatory policies,
and drug reimbursement policies; and
- To propose future oncology policies supporting the R&D process.]]>http://www.ecancermedicalscience.com/view-article.asp?doi=10.3332/ecancer.2009.137Tue, 31 Mar 2009 00:00:00 GMT
Methods: An interdisciplinary team defined the alerts and the actions to be taken in response; recipients of the alert messages were identified and software was programmed. Program features were created so their employment would generate a prompt notification of clinically critical results. After a training period, the program was introduced in the hospital routine.

Results: There were a total of 150 generated alerts; the main alert related to microorganisms requiring prompt patient isolation and/or public notification. Clinical use of the program was relevant in detection and immediate notification of Cytomegalovirus active infection in stem cell recipients and central venous catheter – related candidemia: the prompt administration of adequate treatment was possible hours in advance compared to the previous approach.
Conclusions: A laboratory-based automated surveillance system is effective in facilitating the management of NIs; its clinical employment also leads to important clinical advantages in patient care.
]]>http://www.ecancermedicalscience.com/view-article.asp?doi=10.3332/ecancer.2008.100Wed, 12 Nov 2008 00:00:00 GMT
Chemoprevention describes the potential of chemicals to intervene and block multistage carcinogenesis. Aspirin (acetylsalicylate) is showing cancer chemopreventive potential and the medicine has public health potential given that low-doses also reduce the risk of cardiovascular events by up to 30%. Whilst recognising that aspirin has undesirable effects, perhaps the medicine may compliment other cancer control programmes such as screening and lifestyle measures. Furthermore, perhaps the cancer chemopreventive potential of aspirin might be mediated, at least in part, by salicylate which is present in fruits and vegetables. Salicylate might therefore be considered to be a nutraceutical. Furthermore, there are a number of matters that arise including the potential for the public health field to further advocate the self-care preventive agenda, which might include aspirin. Perhaps it is now timely for a conference on the public health potential of aspirin to be convened.

Key words :
aspirin, cancer control, salicylate, nutraceutical, public health
]]>http://www.ecancermedicalscience.com/view-article.asp?doi=10.3332/eCMS.2008.84Tue, 20 May 2008 00:00:00 GMT
This report summarises the key findings and conclusions of the Eurocan+Plus Project which ran between October 2005 and December 2007, and outlines proposals for action in the short and the longer term.

Participants in the Project represented themselves and not the institution where they work. The Project was in no way a formal collaboration between any governmental body, funding agency, research or medical institution of any of the 27 EU Member States. In this respect, proposals in this Summary Report and in other deliverables in no way represent a formal commitment ofany governmental or non-governmental institution for any idea proposed by the Project.

For more information on the topics developed in this report, interested readers are invited to consult the reports issued by the different Work Packages. These reports can be consulted on the Project website www.eurocanplus.eu.]]>http://www.ecancermedicalscience.com/view-article.asp?doi=10.3332/ecancer.2008.53Tue, 18 Sep 2007 00:00:00 GMT